'''Etalocib''' is a drug candidate that was under development for the treatment of various types of cancer.<ref>{{Cite journal | pmid = 24346102| year = 2014| author1 = Jänne| first1 = P. A.| title = Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer| journal = Journal of Thoracic Oncology| volume = 9| issue = 1| pages = 126-31| last2 = Paz-Ares| first2 = L| last3 = Oh| first3 = Y| last4 = Eschbach| first4 = C| last5 = Hirsh| first5 = V| last6 = Enas| first6 = N| last7 = Brail| first7 = L| last8 = von Pawel| first8 = J| doi = 10.1097/JTO.0000000000000037}}</ref> It acts as a [[leukotriene B4 receptor]] [[Leukotriene antagonist|antagonist]] and a [[PPARγ agonist]].<ref>{{Cite journal | pmid = 19190780| year = 2008| author1 = Adrian| first1 = T. E.| title = The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer| journal = PPAR Research| volume = 2008| pages = 827096| last2 = Hennig| first2 = R| last3 = Friess| first3 = H| last4 = Ding| first4 = X| doi = 10.1155/2008/827096| pmc = 2631651}}</ref>
